Mavenclad has become the multiple sclerosis therapy of choice for one in five neurologists in Germany and the United Kingdom, according to a Spherix Global Insights survey.
Meanwhile, many ... Read more
Apitope and Merck KGaA announced that they have entered into an exclusive agreement regarding ATX-MS-1467, a potential disease-modifying therapy for multiple sclerosis (MS). Under its terms, Apitope will regain full global ... Read more
EMD Serono, the U.S. and Canadian subsidiary and biopharmaceutical business of Merck KGaA, focuses exclusively on specialty care. With expertise in fertility, endocrinology, oncology and neurology, the company is ... Read more
The nonprofit organization Accelerated Cure Project for Multiple Sclerosis is going to sponsor the launch of the Optimizing Treatment – Understanding Progression (OPT-UP) study in collaboration with ... Read more
Pin It on Pinterest